SNX17 and myasthenia gravis: Based on the above mechanism, upregulation of SNX17 in the gastrocnemius muscle of EAMG mice can significantly improve the fragmented morphology of AChR at the NMJ, alleviate the pathological damage of muscle fibers and restore leg muscle weakness to a certain extent, revealing that SNX17 may be a future MG therapy new target.